A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation.

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs Linaclotide (Primary)
  • Indications Constipation; Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2013 Pooled analysis presented at the 21st United European Gastroenterology Week.
    • 14 May 2013 Data will be presented at the 2013 Digestive Disease Week annual meeting, according to an Ironwood Pharmaceuticals,and Forest Laboratories media release.
    • 18 Sep 2012 Results published in the American Journal of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top